Wearable Technology for Personalised Physical Activity Feedback in Cardiac Patients: a Feasibility Study (ACTIVE-CR)

February 2, 2025 updated by: Daniella Springett, University of Bath

Wearable Technology for Personalised Physical Activity Feedback in Cardiac Patients: a Feasibility

Cardiac rehabilitation (CR) is a comprehensive, long-term secondary care programme offered to individuals after a heart attack to aid recovery and prevent further illness. If properly implemented, CR is highly effective at reducing cardiac mortality, re-event, and re-admissions. Despite the well-established benefits, less than 50% of eligible UK patients enrol on a CR program. Among those who do begin CR in the UK, drop-out rates of 12-55% have been reported. If the take up of CR were increased to 65% it would reduce readmissions by a third and save approximately £100 million per year.

Physical activity (PA) is the cornerstone of CR. With recent advances in wearable activity monitors, accurate and objective assessment of free-living PA is now possible. It is increasingly apparent that the health benefits of PA can be achieved in many ways, and multiple dimensions (or aspects) of PA are independently important. The most sophisticated wearable devices can be used to capture these different dimensions and provide a more comprehensive evaluation of free-living PA - enabling patients to understand their individual PA in the context of guidelines - and offering more behavioural options and personalised advice.

In prior work, the investigators have developed a digital system for patients to self-manage their PA. This system comprises a wearable wrist-mounted accelerometer, bespoke digital platform, plus remote virtual support. The digital system has been customised for CR based on qualitative research in cardiac patients and practitioners - who found PA feedback to be understandable and motivating - and a route to address barrier to taking part in CR. This study aims to examine the feasibility of delivering a 6-week trial of a remote, technology-enabled physical activity intervention to patients who were unable to take up or dropped out of CR in the last 12 months.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Current provision of cardiac rehabilitation in the UK is only taken up by <50% of eligible patients, despite the importance of attending for managing symptoms, reducing hospital readmissions and mortality, and improving quality of life. Widely reported factors related to non-attendance include employment commitments, difficulties with transport, lack of time, distance to travel and embarrassment related to attending rehabilitation. The use of home-based programmes permits greater flexibility of CR delivery, as patients are able to complete their programme at a place and time that suit them, as well as increasing access for those who are unable to travel or do not live in close proximity to face-to-face classes. However, current home-based approaches are lacking in objective monitoring of patients and strategies to increase physical activity are limited, despite it being a core component of CR. It is increasingly apparent that the health benefits of physical activity can be achieved in many ways, and multiple dimensions (or aspects) of physical activity are independently important.

Our past research shows that many people misjudge their physical activity status because they do not have access to accurate personalised information. With recent advances in wearable activity monitors, accurate and objective assessment of daily physical activity is possible. The most sophisticated wearable devices can now be used to capture multiple dimensions of physical activity and thus improve the depth and quality of feedback provided to individuals. To date, technology-based physical activity interventions in CR have primarily targeted unidimensional physical activity outcomes, such as step counts and sedentary behaviour.

Multidimensional feedback provides greater awareness, insight, and a more complete understanding of personal physical activity; enabling individuals to take greater responsibility for managing their behaviour and in the context of physical activity guidelines. In addition, a multidimensional approach offers more behavioural options and personalised advice.

Therefore, this study aims to examine the feasibility of delivering a 6-week trial of a remote, technology-enabled physical activity intervention to patients who were unable to take up or dropped out of CR. This study addresses several further shortcomings of previous research in this area: 1) the lack of grounding in psychological behaviour change theory, 2) the lack of objective monitoring for physical activity in CR, and 3) the need for support from practitioners and/or trainers to facilitate physical activity behaviour change.

Study Type

Interventional

Enrollment (Actual)

33

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria: Patients will be recruited in line with British Association for Cardiovascular Prevention and Rehabilitation (BACPR) guidelines, which states that the following priority patient groups shall be offered CR irrespective of age, sex, ethnic group, and clinical condition:

  • Acute coronary syndrome
  • Coronary revascularisation
  • Heart failure

Other patient groups known to benefit:

  • Stable angina
  • Peripheral arterial disease
  • Post-cerebrovascular event
  • Post-implantation of cardiac defibrillators and resynchronisation devices
  • Post-heart valve repair/replacement
  • Post-heart transplantation and ventricular assist devices
  • Adult congenital heart disease

Participants must also:

  • Have access to a smart phone or tablet and the internet
  • Have declined or dropped out of CR in the last 12 months

Exclusion Criteria: Patients who were not referred/deemed eligible for CR (assessed by clinical care team)

  • No access to the internet and/or a smart phone
  • Individuals who have completed CR in the last 12 months
  • Unable to read English
  • Unable to understand written or verbal information

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ACTIVE-CR INTERVENTION
Participants will complete a 6-week remote, technology-based physical activity intervention named ACTIVE-CR, in which they will be required to wear a wrist worn monitor to measure daily physical activity. Participants will be able to view their physical activity feedback on a web-based platform and will receive three online trainer sessions across the 6 weeks to help them to understand and interpret their data.
The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
No Intervention: CONTROL
Participants in the control group will receive usual care from their healthcare team (if relevant) and will be invited to have an assessment at baseline and 6-weeks. Control participants will not receive any form of intervention. At the end of the study, control participants will receive a summary of their physical activity data measured at baseline and 6-weeks (in a booklet format with guidance on how to interpret and use the information).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility: study recruitment
Time Frame: 6-weeks
Assess recruitment rates, defined as the proportion of eligible patients who accept the invitation to participate in the study.
6-weeks
Feasibility: retention
Time Frame: 6-weeks
Examine retention and adherence: defined as the proportion of participants who complete the study
6-weeks
Feasibility: adherence
Time Frame: 6-weeks
Examine adherence: defined as the proportion of online trainer sessions completed and platform usage
6-weeks
Feasibility: acceptability
Time Frame: 6-weeks
Explore the acceptability of the ACTIVE-CR intervention (in terms of affective attitude, burden, perceived effectiveness, ethicality, intervention coherence, opportunity costs, and self-efficacy) using The Theoretical Framework of Acceptability (TFA) Questionnaire
6-weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Seven day physical activity measurement using a research grade device
Time Frame: 6-weeks
A wrist worn physical activity monitor will be used to quantify the following physical activity measures derived from energy expenditure: sedentary time, and light, moderate, vigorous and very vigorous intensities of activity
6-weeks
Weight
Time Frame: 6-weeks
Kilograms
6-weeks
Height
Time Frame: 6-weeks
Centimetres
6-weeks
Waist circumference
Time Frame: 6-weeks
Centimetres
6-weeks
Systolic and diastolic blood pressure
Time Frame: 6-weeks
Measured in millimetres of mercury (mmHg)
6-weeks
Cholesterol levels (Low-density lipoproteins, high-density lipoproteins, total cholesterol)
Time Frame: 6-weeks
Measured in millimoles per litre of blood
6-weeks
Triglyceride levels
Time Frame: 6-weeks
Measured in millimoles per litre of blood
6-weeks
Functional capacity
Time Frame: 6-weeks
Measured by the 6-minute walk test (metres)
6-weeks
Hospital Anxiety and Depression Scale
Time Frame: 6-weeks
Score 0-7 represents "normal," 8-10 "mild," 11-14 "moderate," and 15-21 "severe."
6-weeks
Dartmouth COOP Functional Assessment Charts
Time Frame: 6-weeks
Overall quality of life, physical function, social function, pain. 9 questions, each with answers ranging from 1-5. Possible scores 9-45. The higher the score, the worse the outcome
6-weeks
Behavioural Regulation in Exercise Questionnaire-3
Time Frame: 6-weeks
6-weeks
The Exercise Self-Efficacy Scale
Time Frame: 6-weeks
Rating of participant's degree of confidence to 18 statements by recording a number from 0 to 100% for each one. The higher the score, the higher the degree of confidence.
6-weeks
International Physical Activity Questionnaire
Time Frame: 6-weeks
Self-report measure for physical activity
6-weeks
Health Care Climate Questionnaire (short-form)
Time Frame: 6-weeks
6 items, used to assess participant's perceptions of the degree to which their trainer was autonomy supportive. The scale ranges from 1-7 (scores therefore range from 6-42). The higher the score, the better the participant's perception of support from the trainer
6-weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Oliver Peacock, PhD, University of Bath

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2023

Primary Completion (Actual)

March 31, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

October 19, 2022

First Submitted That Met QC Criteria

October 31, 2022

First Posted (Actual)

November 3, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 2, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ACTIVE-CR-V1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on ACTIVE-CR

Subscribe